skip to main content
UK Health Security Agency

MCF7/AnaR-2

MCF7/AnaR-2

Catalogue No.

16022517

Cell Line Name

MCF7/AnaR-2

Cell Line Description

The MCF7/AnaR-2 cell line was developed as a model of resistance to anti-cancer treatment with aromatase inhibitors. This breast cancer cell line resistant to the aromatase inhibitor anastrozole and is oestrogen receptor positive. Anastrozole-resistant cell lines were established from MCF7 cells grown in medium with 10% newborn calf serum (NCS) and 10⁻⁷ M testosterone. A culture of MCF7 cells were treated with 10⁻⁷ M anastrozole for one week, trypsinized and seeded in serial dilutions in 24-well plates. Single colonies were transferred to new wells and gradually expanded in medium with anastrozole. After ~2-3 months, the isolated colonies gave rise to anastrozole-resistant cell lines, which could be grown in nastrozole containing medium with a weekly split ratio of ~1:25.

General Info

Species

Human

Unique to ECACC

Yes

Also Known As

MCF7/AnaR2, MCF7AnaR2, MCF-7/AnaR-2

Release Conditions

Restricted - commercial organisations are required to complete the 'Cell Line Release Authorisation for Research Use in Commercial Organisations' release conditions form in the supporting documents section.

Characteristics

Receptors

This breast cancer cell is oestrogen receptor positive and resistant to the aromatase inhibitor anastrozole.

Products

Related cell lines: LetR-1, LetR-2, LetR-3 and LetR-4 resistant to the non-steroidal AI, letrozole.- ExeR-1, ExeR-2, ExeR-3 and ExeR-4 resistant to the steroidal AI, exemestane.- AnaR-1, AnaR-3 and AnaR-4 resistant to the non-steroidal AI, anastrozole.

Tissue of Origin

Breast

Morphology

Polygonal epithelium

DNA profile (STR Profile)

Amelogenin: X

CSF1PO: 10

D3S1358: 16

D5S818: 11, 12

D7S820: 9

D8S1179: 10, 14

D13S317: 11

D16S539: 11, 12

D18S51: 14

D21S11: 30

FGA: 19, 23, 25

Penta D: 12

Penta E: 7, 12

TH01: 6

TPOX: 9, 12

vWA: 14, 15

Applications

Third generation aromatase inhibitors (AIs) have proven to be effective treatment for estrogen receptor positive (ER+) breast cancer. They are recommended as first line endocrine therapy for post-menopausal ER+ breast cancer patients, making up the majority of breast cancer patients. However; a major problem is development of resistance against AIs. Since molecular mechanisms of AI resistance are largely undisclosed, the development of cell lines resistant to the non-steroidal AI anastrozole allows the study of the molecular basis for resistance to AIs to unravel new targets for treatment.

Disease

Pleural Effusion of a Ductal Carcinoma

Culture Conditions

Cell Type

Epithelial

Subculture Routine

Split sub-confluent cultures at 70-80% confluency. Subculture cells using 0.05% trypsin/EDTA solution or TrypLE Express™ (1X), without phenol red, and wash with phosphate- buffered saline (PBS) . Pellet cells by centrifugation (~100 x g) and re-suspend in growth medium. Initiate the culture at a dilution of approximately 1:3 to 1:6 i.e. seeding at 2-4 x 10⁴ cells/cm². Incubate cultures in 5% CO₂ at 37°C. Recommend media changes every 2-3 days. It is recommended that upon resuscitation the cells are washed PBS or serum-free medium, pelleted by centrifugation and re-suspended in growth medium prior to initiation of culture.

Culture Medium

Phenol-red-free DMEM/F12 medium supplemented with 10% Newborn Calf Serum (NCS), 2.5 mM Glutamax, 6 ng/ ml insulin, 0.1 µM testosterone and 0.1 µM anastrozol. Cryopreserve cells in Newborn Calf Serum (90%) and dimethyl sulphoxide (DMSO) (10%).

Growth Mode

Adherent

Additional Info

Depositor

Ximbio (formerly known as Cancer Research Technologies Limited)

Country of Origin

Denmark

Hazard Group (ACDP)

Hazard Group (ACDP) 2

Applications

References

Hole et al. 2015. Breast Cancer Res Treat. 149(3):715-26. PMID: 25667100. Hole et al. 2015. Int J Oncol. 46(4):1481-90. PMID: 25625755

Available Formats

  • Frozen

If use of this culture results in a scientific publication, it should be cited in the publication as: MCF7/AnaR-2 (ECACC 16022517).

Unless specified otherwise, at ECACC we routinely handle all of our cell lines at containment level 2 in accordance with the ACDP guidelines (Advisory Committee on Dangerous Pathogens) (UK). All cell cultures have the potential to carry as yet unidentified adventitious agents. It is the responsibility of the end user to ensure that their facilities comply with biosafety regulations for their own country. ACDP Guidance: Biological agents: Managing the risks in laboratories and healthcare premises.

The Culture Collections represent deposits of cultures from world-wide sources. While every effort is made to ensure details distributed by Culture Collections are accurate, Culture Collections cannot be held responsible for any inaccuracies in the data supplied. References where quoted are mainly attributed to the establishment of the cell culture and not for any specific property of the cell line, therefore further references should be obtained regarding cell culture characteristics. Passage numbers where given act only as a guide and Culture Collections does not guarantee the passage number stated will be the passage number received by the customer.

Cultures supplied by Culture Collections are for research purposes only. Enquiries regarding the commercial use of a cell line are referred to the depositor of the cell line. Some cell lines have additional special release conditions such as the requirement for a material transfer agreement to be completed by the potential recipient prior to the supply of the cell line. Please view the Terms & Conditions of Supply for more information.